Management Team

Brian Windsor, Ph.D.

Chief Executive Officer

Brian Windsor, Ph.D.

Brian Windsor, Ph.D.

Chief Executive Officer

Dr. Brian Windsor has served as President and CEO of Lung Therapeutics since July of 2013. He has spent the last 20 years in the formation and management of life science companies and has led technology development and licensing to major pharmaceutical and biotech companies.  Dr. Windsor brings leadership experience in pharmaceutical drug development, and he previously served as President of Enavail, LLC, a specialty pharmaceutical manufacturing company developing unique formulations for superior drug performance. While at Enavail, Dr. Windsor oversaw all aspects of pharmaceutical drug development, including drug selection, regulatory strategy, preclinical and clinical strategy, GMP manufacturing, and strategic partnering for pharma products.

Prior to his role with Enavail, Dr. Windsor directed portfolio company management for Emergent Technologies Inc. (ETI), an early stage technology venture creation and management company. During his tenure at ETI, Dr. Windsor served as Managing Director or President for ten of ETI’s portfolio companies and was involved in the conception, technology licensing, corporate and technical strategic planning, launch, and business development of all of these ventures. Applications areas of these companies span diverse segments within life and material sciences and include pharmaceutical development and manufacturing, drug delivery, and biotechnology. 

Prior to joining ETI, he was Founder and Vice President of R&D for Texagen, Inc., a startup focused on genetic and chemical methods for overcoming mechanisms of drug resistance important to medicine and agriculture. At Texagen, he directed outsourced research efforts at university labs and third-party contract research companies, and he interfaced with corporate partners interested in feasibility studies and in-licensing discussions.

He holds a Ph.D. in Molecular Biology from The University of Texas at Austin and is an inventor on multiple patents and patent applications.

Charles Garner

Chief Financial Officer

Charles Garner

Charles Garner

Chief Financial Officer

Charles Garner joined Lung Therapeutics in 2018 as Chief Financial Officer. Mr. Garner brings over 20 years of investment banking, corporate finance, business development and financial operational experience to Lung Therapeutics. Most recently, Mr. Garner was a life science industry consultant to private and public life sciences companies, providing financial and advisory services. Before this, Mr. Garner was Chief Financial Officer and Chief Business Officer for Recro Pharma, Inc., successfully leading the company’s initial public offering and acquisition of select assets from Alkermes, plc. Mr. Garner began his professional career as a certified public accountant with PricewaterhouseCoopers and, while an investment banker for Deutsche Bank AG, raised or advised on over $8 billion of financial and advisory transactions for healthcare clients. Mr. Garner received his Bachelor’s degree in Business Administration, high distinction, with a concentration in Accounting and Finance from the University of Michigan.

Cory M. Hogaboam, Ph.D.

Cory M. Hogaboam, Ph.D.

Chief Scientist

Dr. Cory M. Hogaboam is a Professor of Medicine in the Women’s Guild Lung Institute at Cedars Sinai Medical Center.  Dr. Hogaboam is also an Adjunct Professor of Pathology at the University of Michigan Medical School. His research group currently employs genomic, proteomic and bioinformatic approaches to analyze mechanisms contributing to fibrotic and immune system-directed responses in idiopathic pulmonary fibrosis (IPF), lung cancer, sarcoid, hypersensitivity pneumonitis, chronic obstructive pulmonary disease (COPD), and asthma utilizing human tissue- and blood-derived cells including fibroblasts, mesenchymal progenitors and various immune cell types that are typically present in abundance in these pulmonary diseases.  His group also uses translational approaches through the development of humanized SCID mouse models of IPF, cancer, and asthma.   He earned a Bachelor of Science degree in Zoology from the University of Calgary, AB, Canada in 1989.  He also holds a Doctorate in Pharmacology (1993) from the same institution. Dr. Hogaboam then engaged in Postdoctoral training in Immunology at McMaster University, Hamilton, ON, Canada from 1993 to 1996.  In 1996, Dr. Hogaboam joined the faculty of the Department of Pathology at the University of Michigan Medical School as a Visiting Scholar. He became a faculty member of the Department at the rank of Research Investigator in 1998, Assistant Professor in 2002, Associate Professor in 2004, and full Professor in 2008.  Dr. Hogaboam joined the faculty at Cedars Sinai Medical Center in September of 2013. Hogaboam is a member of several professional organizations including the American Association of Immunologists, the American Thoracic Society, and the American Association of Allergy, Asthma and Immunology.  He is presently serving on the editorial board of the American Journal of Respiratory and Critical Care Medicine and the Journal of Clinical Investigation Insight.  Dr. Hogaboam has authored or co-authored approximately 281 peer-reviewed manuscripts and 31 book chapters.  He has authored or co-authored 11 patents on therapeutic interventions for lung and liver.  Dr. Hogaboam has received financial research support from the National Institutes of Health, American Lung Association, Canadian Institutes of Health Research, and several Industry sponsors.  

Sharon Morriss, Ph.D.

SVP, Clinical Development

Sharon Morriss, Ph.D.

Sharon Morriss, Ph.D.

SVP, Clinical Development

Dr. Sharon Morriss joined Lung Therapeutics in June 2021 as the SVP, Clinical Development. Dr. Morriss has more than fifteen years of experience leading clinical development teams from pre-clinical through to commercialization for biotechnology companies.

In her most recent position she served as SVP, Clinical Development Operations at Apellis Pharmaceuticals, where her numerous responsibilities included the advancement of the company’s rare disease and ophthalmology clinical portfolio. This led to the FDA approval of EMPAVELIä (pegcetacoplan), a targeted C3 therapy for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). Dr. Morriss built and led the global clinical development operations team, creating a team to advance the diverse clinical platform through to registrational clinical studies in hematology, nephrology, neurology, and ophthalmology. Dr. Morriss also chaired the Joint Development Committee for Apellis’ global co-development alliance for systemic pegcetacoplan with Swedish Orphan Biovitrum (Sobiä).

Prior to joining Apellis, Dr. Morriss worked in roles of increasing responsibility at Shire Pharmaceuticals (now Takeda) where she oversaw the Global Clinical Program teams, supporting the global development of the ophthalmology and hematology portfolios. Dr. Morriss started her career in both Clinical Scientist and CRA positions for United Therapeutics, PPD and Sanofi-Aventis.

Dr. Morriss holds a BSc (Hons) in Zoology (Parasitology) from the University of Aberdeen in Scotland, and a PhD in Molecular Biology/Biochemistry from the University of Stirling, Scotland.

Matt Karpen

Matt Karpen

VP, CMC

Matt Karpen joined Lung Therapeutics in 2018 as Director of CMC. Mr. Karpen brings approximately 20 years of biopharmaceutical experience to Lung Therapeutics, including various leadership positions in process development, process engineering, process scale-up, and technology transfer, cGMP operations support, and clinical and commercial manufacturing. Most recently, Mr. Karpen was a senior leader in the process validation strategy group within technical operations at Shire. There he developed and implemented innovative process qualification, characterization and controls strategies in support of several orphan drug and breakthrough therapies submissions. Prior to this, Mr. Karpen held various leadership roles at Amgen where he developed and implemented industry-leading strategies for process scale-up and tech transfer, product changeover and new product introduction, and supported the “manufacturing of the future” platform. At Amgen, Mr. Karpen was part of several successful commercial regulatory submissions. Mr. Karpen began his biopharmaceutical career at Pfizer within the process development organization and performed pilot plant operations, tech transfer and supported the start-up of a cGMP clinical manufacturing facility. Mr. Karpen received his Bachelor of Science in Engineering from the University of Dayton. He is published in BioPharm International and is a co-author of PDA Technical Report 56.

Misty Hickman

Director of Operations

Misty Hickman

Misty Hickman

Director of Operations

Misty Hickman has provided accounting and operational consulting services to Lung Therapeutics since 2013.  In 2019, Ms. Hickman came on-board full time as Director of Operations, and is now responsible for all aspects of business operations, including legal and vendor support, HR, and compliance.  She also continues to support the finance and accounting functions where needed. Ms. Hickman began her career in public accounting and spent several years with a local firm in Louisiana before moving to Texas in 2006.  Since then, she has worked for and consulted for several startups and pre-revenue companies, with a focus on establishing scalable policies and procedures for young companies.  She has over 20 years of experience in finance, accounting, and operations.  Ms. Hickman received her Bachelor of Science in Business Administration with a concentration in Accounting degree from the University of Louisiana at Lafayette. 

Kristie Lauterbach

Director of Quality Assurance

Kristie Lauterbach

Kristie Lauterbach

Director of Quality Assurance

Kristie Lauterbach, Director of Quality Assurance, brings over 25 years of progressive quality leadership and experience in the pharmaceutical industry to Lung Therapeutics. Most recently, Ms. Lauterbach provided Quality leadership at Takeda, where she had oversight for the technical transfer and supplier management of two key products from API through packaging operations. Prior to Takeda, Ms. Lauterbach was the Head of Quality for Catalent Pharma Solutions, responsible for quality assurance, quality control, validation, GMP Compliance, DEA Compliance, Microbiology, document control, batch release and supplier management at one of their key oral solid dosage sites. Before Catalent, Ms. Lauterbach spent ten years at Eli Lilly and Co., where she enjoyed leadership roles of increasing responsibility, including oversight of parenteral manufacturing, supplier quality management, and oversight for Lilly’s external partners across medical/clinical development. Ms. Lauterbach began her career at Amour Pharmaceutical (now known as CSL Behring) as an Aseptic Technician progressing into quality assurance and manufacturing leadership roles. Ms. Lauterbach holds a Bachelor’s degree in Biology and an MBA from Olivet Nazarene University.